Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.
J Immunother Precis Oncol. 2024;7(4):255-262 - PMID: 39524465 - PMCID: PMC11541930 - DOI: 10.36401/JIPO-24-6
Combination CXCR4 and PD1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma.
Cancer Immunol Res. 2024;:ePub - PMID: 39514263 - DOI: 10.1158/2326-6066.CIR-24-0324
Fluorescence Lifetime Imaging Enables In vivo Quantification of PD-L1 Expression and Inter-tumoral Heterogeneity.
Cancer Res. 2024;:ePub - PMID: 39514403 - DOI: 10.1158/0008-5472.CAN-24-0880
Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma.
Oncology. 2024;:1-8 - PMID: 39427654 - DOI: 10.1159/000541250
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
ACS Pharmacol Transl Sci. 2024;7(10):3155-3169 - PMID: 39416967 - PMCID: PMC11475281 - DOI: 10.1021/acsptsci.4c00358
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab.
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
J Clin Oncol. 2024;42(36):4282-4293 - PMID: 39298718 - DOI: 10.1200/JCO.24.00003
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Cancer tissue of origin constrains the growth and metabolism of metastases.
Nat Metab. 2024;6(9):1668-1681 - PMID: 39160333 - PMCID: PMC11450831 - DOI: 10.1038/s42255-024-01105-9
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2024;11:455-461 - PMID: 38463542 - PMCID: PMC10921889 - DOI: 10.2147/JHC.S452564
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Cancer Immunol Res. 2024;12(4):400-412 - PMID: 38260999 - PMCID: PMC10985468 - DOI: 10.1158/2326-6066.CIR-23-0486
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Radiother Oncol. 2024;192:110091 - PMID: 38224917 - PMCID: PMC10905770 - DOI: 10.1016/j.radonc.2024.110091
15